EUVIMEDEUVIMED entdecken
Crossref

Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population

Keiko Hikino iD, Kensuke Shoji, Jumpei Saito iD, Koya Fukunaga, Xiaoxi Liu, Toshihiro Matsui, Tomoyuki Utano, Akira Takebayashi, Daisuke Tomizawa, Motohiro Kato, Kimikazu Matsumoto, Takashi Ishikawa und 5 weitere

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Keiko Hikino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan. Hauptthemen laut MEDLINE: Voriconazole, Cytochrome P-450 CYP2C19, Antifungal Agents, Thrombocytopenia. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Research Foundation for Clinical Pharmacology, Japan Society for the Promotion of Science KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The influence of CYP2C19 polymorphisms on voriconazole plasma concentrations is recognized, but its extent, other contributing factors and risks for adverse reactions remain under‐explored.

Methods

This study focused on Japanese paediatric patients recruited between 2020 and 2022 treated with voriconazole. We specifically investigated the occurrence of cholestasis and thrombocytopenia as adverse reactions of voriconazole. Voriconazole plasma levels were modelled in a previous study using a population pharmacokinetics approach. Missing values were estimated with a Bayesian method in Phoenix NLME. We analysed CYP2C19*2 , CYP2C19*3 and CYP2C19*17 . Clinical and laboratory data were collected before and after voriconazole treatment.

Results

Among the 60 patients (mean age: 6.5 years; 53.3% male), 38 had haematological malignancies, 18 inborn errors of immunity, 2 solid tumours and 2 other diseases. Adverse reactions occurred in 12 patients. The voriconazole plasma concentrations were significantly higher in those experiencing these adverse reactions (mean normalized concentrations: 0.66 in cases vs . −0.16 in controls, P = .025), with a trend towards higher concentrations in carriers of the CYP2C19*2 or *3 alleles (mean normalized concentrations: 0.98 in carrier cases vs . 0.016 in noncarrier cases, P = .14). A predictive model for voriconazole concentrations, incorporating carriership of CYP2C19*2 or *3 , C‐reactive protein levels, and platelet counts, showed a summed variance explained of 23.6% with the variance attributable to CYP2C19*2 or *3 carrier status alone was 2.6%. Including carrier status improved the area under the receiver operating characteristic curve for predicting adverse reactions to 0.70.

Conclusions

Our findings underscore the role of the CYP2C19 polymorphism in voriconazole‐induced thrombocytopenia and cholestasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleCytochrome P-450 CYP2C19Antifungal AgentsThrombocytopeniaCholestasisHumansMaleChildFemaleChild, PreschoolAdolescentInfantPolymorphism, GeneticBayes TheoremJapan

Stichwörter der Autor:innen

CYP2C19pharmacogenomicsvoriconazole

Substanzen

VoriconazoleCytochrome P-450 CYP2C19Antifungal AgentsCYP2C19 protein, human

Autor:innen und Institutionen

  • Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan.
  • Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan.
  • Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan.
  • Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Division of Immunology, National Center for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Keiko Hikino, Jumpei Saito

Förderung

  • Japan Society for the Promotion of Science
  • Japan Research Foundation for Clinical Pharmacology
  • Japan Society for the Promotion of Science KAKENHI

Zitieren

APA

Hikino, K., Shoji, K., Saito, J., Fukunaga, K., Liu, X., Matsui, T., Utano, T., Takebayashi, A., Tomizawa, D., Kato, M., Matsumoto, K., Ishikawa, T., Kawai, T., Nakamura, H., Miyairi, I., Terao, C., & Mushiroda, T. (2025). Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70026

Vancouver

Hikino K, Shoji K, Saito J, Fukunaga K, Liu X, Matsui T, et al. Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70026

BibTeX
@article{Hikino2025,
  author = {Hikino, Keiko and Shoji, Kensuke and Saito, Jumpei and Fukunaga, Koya and Liu, Xiaoxi and Matsui, Toshihiro and Utano, Tomoyuki and Takebayashi, Akira and Tomizawa, Daisuke and Kato, Motohiro and Matsumoto, Kimikazu and Ishikawa, Takashi and Kawai, Toshinao and Nakamura, Hidefumi and Miyairi, Isao and Terao, Chikashi and Mushiroda, Taisei},
  title = {Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70026}
}
Kostenlos starten →